(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the nation's first cell-based flu vaccine, a product from Novartis that uses technology that could help vaccinate more Americans in a pandemic but still has many of the same limitations of older egg-based flu vaccines.
(CIDRAP News) Antiviral resistance and the global economic downturn might present new obstacles for corporate antiviral stockpiling, but two medical experts today said the medications are still quick, reliable tools that can help preserve business continuity in an influenza pandemic.
(CIDRAP News) Novartis, the Swiss-based drug manufacturer, today announced plans to build what it says will be the first US plant to make cell-culture-based influenza vaccines.
The facility will be built in Holly Springs, N.C., at a total cost of about $600 million, the company said in a news release. It will be able to produce about 50 million doses of seasonal trivalent (three-strain) flu vaccine annually.
(CIDRAP News) The United States proposed today that a small group of experts be appointed immediately to plan a fast response in case an influenza pandemic erupts, as an international conference on avian and pandemic flu continued in Geneva.